Amneal Pharmaceuticals, Inc. (AMRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Net revenue | 724,508 | 695,420 | 702,468 | 701,780 |
| Cost of goods sold | 438,255 | 439,529 | 432,910 | 451,833 |
| Gross profit | 286,253 | 255,891 | 269,558 | 249,947 |
| (credit) charges related to legal matters, net | 390 | - | 149 | -699 |
| Intellectual property legal development expenses | 2,017 | 1,767 | - | - |
| Other operating (income) expense | - | 5,122 | - | - |
| Research and development | 47,964 | 40,040 | 61,097 | 36,054 |
| Restructuring and other charges | 1,024 | 571 | 172 | 220 |
| Selling, general and administrative | 124,266 | 118,288 | 118,692 | 116,462 |
| Change in fair value of contingent consideration | - | - | 1,030 | - |
| Intellectual property legal development expenses | - | - | 1,967 | 1,042 |
| Operating income (loss) | 111,372 | 100,347 | 88,809 | 95,470 |
| Other income, net | 1,604 | 518 | 1,178 | 4,360 |
| Interest expense, net | -65,101 | -56,939 | -65,511 | -65,719 |
| Foreign exchange gain (loss), net | 8,256 | 4,247 | 2,274 | -262 |
| Increase in tax receivable agreement liability | -4,420 | -10,687 | -11,327 | -13,444 |
| Total other expense, net | -59,661 | -62,861 | -73,386 | -75,065 |
| Income (loss) before income taxes | 51,711 | 37,486 | 15,423 | 20,405 |
| Provision for income taxes | 16,101 | 12,868 | 3,666 | 3,618 |
| Net income (loss) | 35,610 | 24,618 | 11,757 | 16,787 |
| Basic (in dollars per share) | 0.07 | 0.04 | - | 0.02 |
| Basic (in shares) | 313,739,000 | 311,054,000 | 309,647,000 | 309,117,000 |
| Diluted (in dollars per share) | 0.07 | 0.04 | - | 0.02 |
| Diluted (in shares) | 322,363,000 | 323,961,000 | 309,647,000 | 318,957,000 |